SYNNESTVEOT & LECHNER LLP

In re Application of Daniel O'Mahony and Michela Seveso Application No. 09/443,780

Page 2 September 30, 2003

## <u>Amendments</u>

## In the Claims

- (Currently amended) An isolated antibody or antibody fragment specific to a domain
  of a gastro-intestinal tract (GIT) targeting agent, said targeting agent comprising
  ZElan033 (PAX2 15 mer) (SEO ID NO:1) a protein that specifically binds to a GIT
  receptor.
- (Original) The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment is selected from the group consisting of a polyclonal antibody, monoclonal antibody, chimeric antibody, single chain antibody, a Fab fragment or a Fab expression library
- 3. (Cancel) The antibody or antibody of fragment of claim 1, wherein the GIT targeting agent is selected from the group consisting of ZEIan033 (PAX2 15 mer) (SEQ ID NO:1), ZEIan088 (HAX42-2 20 mer) SEQ ID NO:2) or ZEIan053 (P31 D-form 16 mer) (SEQ ID NO:3).
- 4. (Withdrawn) A method of making an antibody of antibody fragment of claim 1, comprising the steps of (a) contacting a GIT targeting agent with the immune system of an animal under conditions conducive to formation of antibodies in abody fluid of the animal and (b) recovering the artibody or antibody fragment from the body fluid of the animal.
- (Withdrawn) A method of identifying the presence of a GIT targeting agent in a composition or quantitating the amount of a GIT targeting agent in a composition, wherein the composition comprises the GIT targeting agent bound to an active agent, comprising the steps of (a) contacting an antibody or an antibody fragment specific to a domain of the GIT targeting agent with the composition under conditions conducive to binding between the antibody or antibody fragment and the GIT targeting agent; and

SYNNESPVEDT & LECHNIR LLP

In re Application of Daniel O'Mahony and Michela Seveso Application No. 09/443,780

Page 3 September 30, 2003

(b) detecting the amount of antibody or artibody fragment that specifically binds to the GIT targeting agent.

- 6. (Withdrawn) A method of identifying the location of a GIT targeting agent in a composition, wherein the composition comprises the GIT targeting agent bound to an active agent, comprising the steps of (a) contacting an antibody or antibody fragment specific to a domain of the GIT targeting agent; and (b) visualizing the position of the antibody or antibody fragment that specifically binds to the GIT targeting agent.
- 7. (Withdrawn) The method fo Claim 6, wherein the composition comprises an active agent loaded nano- or microparticle bound to the GIT targeting agent.
- 8. (Withdrawn) A method of identifying the location of a GIT targeting agent following contact of a GIT targeting agent-containing composition with human or animal gastro-intestinal tissue, comprising the steps of (a) contacting an antibody or an antibody fragment specific to a domain of the GIT targeting agent with the composition under conditions conducive to binding between antibody or antibody fragment and the GIT targeting agent; and (b) detecting the location of the antibody or antibody fragment that specifically binds to the GIT targeting agent.
- 9. (Withdrawn) An antibody or antibody fragment of Claim 1, wherein the GIT transport receptor is selected from the group consisting of D2H (domain 387-685) (SEQ ID NO:13), hS1 (domain 272-667) (SEQ ID NO:14), HPT1 (domain 29-273) (SEQ ID NO:15), and hPEPT1 (domain 391-571) (SEQ ID NO:16).
- 10. (Withdrawn) An antibody or antibody fragment of claim 9, wherein the protein comprises either an amino acid sequence selected from the group consisting of SEQ ID NOS: 17-71 or a receptor binding portion of the amino acid sequence.

M

SYNNESTVEDT & LECHNER LLP

In re Application of Daniel O'Mahony and Michela Seveso Application No. 09/443,780

Page 4 September 30, 2003

- 11. (Withdrawn) An antibody or antibody fragment of claim 10, wherein the protein consists of the amino acid sequence selected from the group consisting of SEQ ID NOS: 17-71 or a receptor binding portion of the amino acid sequence.
- 12. (Withdrawn) An antibody or antibody fragment of claim 10, wherein the protein comprises the amino acid sequence selected from the group consisting of SEQ ID NOS:
- 13. (Withdrawn) An antibody or antibody fragment of claim 11, wherein the protein consists of the amino acid sequence selected from the group consisting of SEQ ID NOS: 17-71.
- 14. (Withdrawn) An antibody or antibody fragment of claim 9, wherein the protein consists of an amino acid sequence of not more than 50 amino acids in length, the amino acid sequence is one selected from the group consisting of
  - (a) Xaa<sub>1</sub> Thr Xaa<sub>2</sub> Xaa<sub>3</sub> Ser Xaa<sub>4</sub> Xaa<sub>5</sub> Xaa<sub>6</sub> Asn Xaa<sub>7</sub> Arg (SEQ ID NO: 72), where Xaa<sub>7</sub> is Ser or Thr; Xaa<sub>2</sub> is Arg or Lys; Xaa<sub>3</sub> is Lys or Arg; Xaa<sub>4</sub> is Ser or Leu; Xaa<sub>5</sub> is Arg, Ile, Val, or Ser Xaa<sub>6</sub> is Ser, Tyr, Phe, or His; and Xaa<sub>7</sub> is Pro, His or Arg;
  - (b) Asp Xaa<sub>1</sub> Asp Xaa<sub>2</sub> Arg Arg Xaa<sub>3</sub> Xaa<sub>4</sub> (SEQ ID NO: 73) where Xaa<sub>1</sub> is Ser, Ala, or Gly; Xaa<sub>2</sub> is Val or Gln; Xaa<sub>3</sub> is Pro, Gly, or Ser, and Xaa<sub>4</sub> is Trp or Tyr;
  - (c) Val Arg Ser Gly Cys Gly Xaa<sub>1</sub> Xaa<sub>2</sub> Ser Ser (SEQ ID NO: 74), where Xaa<sub>1</sub> is Ala or Phe; and Xaa<sub>2</sub> is Arg or His;
  - (d) NTRKSSRSNPR (SEQ ID NO: 75);
  - (e) STKRSLIYNHR (SEQ LD NO: 76);
  - (f) STGRKVFNRR (SEQ ID NO: 77);
  - (g) TNAKHSSHNRR (SEQ ID NO: 78);
  - (h) DSDVRRPW (SEQ ID NO: 79);
  - (i) AADQRRGW (SEQ ID/NO: 80);
  - (j) DGRGGRSY (SEQ ID NO: 81);
  - (k) RVRS (SEQ ID NO: \$2);



SYNNESTVEDT & LECHNER LLP

In re Application of Daniel O'Mahony and Michela Seveso Application No. 09/443,780

Page 5 September 30, 2003

- (I) SVRSGCGFRGSS (SEQ D NO: 83);
- (m) SVRGGCGAHSS (SEQ D NO: 84).
- 15. (Withdrawn) An antibody of claim 1.
- 16. (Withdrawn) An antibody of claim 2.
- 17. (Withdrawn) An antibody of claim 3.
- 18. (Withdrawn) An antibody of claim 9.
- 19. (Withdrawn) An antibody of claim 10.
- 20. (Withdrawn) An antibody of claim 11.
- 21. (Withdrawn) An antibody of claim 12.
- 22. (Withdrawn) An antibody of claim 13.
- 23. (Withdrawn) An antibody of claim 14.
- 24. (Withdrawn) An antibody or antibody fragment, said antibody or antibody fragment capable of immunospecifically binding to a protein, said protein being capable of specific binding to a GIT transport receptor.
- 25. (Withdrawn) An antibody or antibody fragment of Claim 24, wherein the antibody or antibody fragment is selected from the group consisting of a polyclonal antibody, monoclonal antibody, chimeric antibody, single chain antibody, a Fab fragment or a member of a Fab expression library.



SYNNESTVEDT & LICHNER LLP


In re Application of Daniel O'Mahony and Michela Seveso Application No. 09/443,780

Page 6 September 30, 2003

- 26. (Withdrawn) An antibody or antibody fragment of claim 24, wherein the protein consists of an amino acid sequence selected from the group consisting of ZElan033 (PAX2 15 mer) (SEQ ID NO:1), ZElan088 (HAX42-2 20 mer) (SEQ ID NO:2) or ZEIan053 (P31 D-form 16 mer) (SEQ ID NO:3).
- 27. (Withdrawn) An antibody or antibody fragment of Claim 24, wherein the GIT transport receptor is selected from the group consisting of D2H (domain 387-685) (SEQ ID NO:13), hS1 (domain 272-667) (SEQ ID NO:14), HPT1 (domain 29-273) (SEQ ID NO:15), and hPEPT1 (domain 391-571) (SEQ ID NO:16).
- 28. (Withdrawn) An antibody or antibody fragment of claim 27, wherein the protein comprises either an amino acid sequence selected from the group consisting of SEQ ID NOS: 17-71 or a receptor binding portion of the amino acid sequence.
- 29. (Withdrawn) An antibody or antibody fragment of claim 28, wherein the protein consists of the amino acid sequence selected from the group consisting of SEQ ID NOS: 17-71 or a receptor binding portion of the amino acid sequence.
- 30. (Withdrawn) An antibody or antibody fragment of claim 29, wherein the protein comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 17-71.
- 31. (Withdrawn) An antibody or antibody fragment of claim 27, wherein the protein consists of the amino acid sequence selected from the group consisting of SEQ ID NOS: 17-71.
- 32. (Withdrawn) An antibody or antibody fragment of claim 24, wherein the protein consists of an amino acid sequence of not more than 50 amino acids in length, the amino acid sequence is one selected from the group consisting of
  - (b) Xaa, Thr Xaa, Xaa, Ser Xaa, Xaa, Xaa, Asn Xaa, Arg (SEQ ID NO: 72), where Xaa, is Ser or Thr; Xaa, is Arg or Lys; Xaa, is Lys or Arg; Xaa, is Ser



E




In re Application of Daniel O'Mahony and Michela Seveso Application No. 09/443,780

Page 7 September 30, 2003

or Leu; Xaa, is Arg, Ile, Val, or Ser; Xaa, is Ser, Tyr, Phe, or His; and Xaa, is Pro, His or Arg;

- (b) Asp Xaa<sub>1</sub> Asp Xaa<sub>2</sub> Arg Arg Xaa<sub>3</sub> Xaa<sub>4</sub> (SEQ ID NO: 73) where Xaa<sub>1</sub> is Ser, Ala, or Gly; Xaa<sub>2</sub> is Val or Gln; Xaa<sub>3</sub> is Pro, Gly, or Ser; and Xaa<sub>4</sub> is Trp or Tyr;
- (c) Val Arg Ser Gly Cys Gly Xaa<sub>1</sub> Xaa<sub>2</sub> Ser Ser (SEQ ID NO: 74), where Xaa<sub>1</sub> is Ala or Phe; and Xaa<sub>2</sub> is Arg or His;
- (d) NTRKSSRSNPR (SEQ ID NO: 75);
- (e) STKRSLIYNHR (SEQ ID NO: 76);
- (f) STGRKVFNRR (SEQ ID NO: 77);
- (g) TNAKHSSHNRR (SEQ ID NO: 78);
- (h) DSDVRRPW (SEQ ID/NO: 79);
- (i) AADQRRGW (SEQ ID NO: 80);
- (j) DGRGGRSY (SEQ LD NO: 81);
- (k) RVRS (SEQ'ID\NO:/82);
- (1) SVRSGCGFRGS (SEQ ID NO: 83);
- (m) SVRGGCGAHSS (SEQ ID NO: 84).
- 33. (Withdrawn) An antibody of claim 24.
- 34. (Withdrawn) An antibody of claim 25.
- 35. (Withdrawn) An antibody of claim 26.
- 36. (Withdrawn) An antibody of claim 27.
- 37. (Withdrawn) An antibody of claim 28.
- 38. (Withdrawn) An antibody of claim 29.





In re Application of Daniel O'Mahony and Michela Seveso Application No. 09/443,780

Page 8 September 30, 2003

39. (Withdrawn) An antibody of claim 30.

141

40. (Withdrawn) An antibody of claim 31.

41. (Withdrawn) An antibody of claim 32.

€-80 E